Tuesday, October 19, 2021

AVIR stock: 70% loss | RHHBY - Roche | Oct 19, 2021

 华盛资讯10月19日讯,美股早盘,Aviragen医疗(AVIR)大幅低开,一度跌超70%。截至发稿,该股跌幅收窄至60%,股价报15.40美元。

消息面上,罗氏(RHHBY)新冠药物合作方Aviragen医疗(Atea Pharma)周二表示,其研制的AT-527型口服新冠药物未能通过一项关键的中期测试。据了解,Aviragen医疗及其合作伙伴罗氏正在重新考虑该药物(AT-527)的持续第三阶段试验。

Atea pharma(AVIR)盘中一度跌超70% 其新冠中期实验未达目标

2021-10-19 23:18凤凰网资讯

凤凰网港股|Atea pharma(AVIR)盘中一度跌超70%,现跌幅收窄至60%,报16.07美元。

罗氏新冠药物合作方Atea Pharma周二表示,其研制的AT-527型口服新冠药物未能通过一项关键的中期测试。

在这项中期试验中,AT-527的表现并没有比安慰剂好上多少。具体来说,无论是接受高、低剂量AT-527治疗的轻到中度Covid-19患者,与服用安慰剂的对照组患者,体内病毒数量并没有明显减少。

该药物由Atea公司研发,罗氏此前以3.5亿美元前期付款和后续里程碑付款获得了AT-527在美国以外治疗COVID-19的权益。

尽管有业内专家认为,本次试验失败可能是招募了过多轻度甚至接种过疫苗的患者,导致了与对照组相比,差异不显著;Atea 首席执行官 Jean-Pierre Sommadossi 也表示,Atea和罗氏正在根据新结果「评估对后期研究的潜在调整方向」。然而,投资者似乎已经否定了该型药的前景,对此并不买账。



















































CVM stock: How to make a series of purchases without headache?

Oct. 19, 2021

Introduction

It is the first time I like to manage myself to practice small trades. I have $450 US dollar gains on CVM stock. My plan is to use those $450 US dollars to purchase CVM stocks, once the gain reaches 5% to 10%, the position will be sold and then put in the waiting list portfolio. I can warm up my trade skills very often. Small trade trains me to work on investment more regularly. 

CVM stock | Oct. 6 purchase 40 shares| Oct. 19 40 shares sold | $44 dollar gain

It is important for me to trade for small amount gain since there is no commission. I also can learn better to manage myself, and understand the market better. 

$44 dollars for two weeks is 10.71% for less than two weeks, and I like to see if I can start to build some positions based on my gain, and then I can keep track of more stock this way. 

This is the way how I spend my leisure time. Enjoy reading. 

One more picture to tell the story


勤劳致富


GRTX stock: 68% plunge | 20 minutes learning about III trial

 MALVERN, Pa., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced results from the Phase 3 ROMAN trial of avasopasem manganese (avasopasem) for severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC) undergoing standard-of-care radiotherapy. The trial did not meet its primary endpoint of reduction in the incidence of SOM. The Company is continuing to analyze the results.

“While the data, as in previous trials, showed reductions in the incidence, duration and severity of SOM, we are surprised and disappointed that the trial did not achieve statistical significance in its primary endpoint,” said Mel Sorensen, M.D., Galera’s President and CEO. “We would like to extend our heartfelt thanks to the patients who participated in this trial while they underwent radiotherapy for head and neck cancer. As we evaluate next steps for this program, we remain committed to our goal of transforming radiotherapy in cancer treatment with our selective dismutase mimetics.”

Key findings include:

  • 16% relative reduction in the incidence of SOM in the avasopasem treatment group (54%) vs. placebo group (64%) (p=0.113) (primary endpoint)

  • 56% relative reduction in the number of days of SOM in the avasopasem treatment group (8 days) vs. placebo group (18 days) (p=0.011) (secondary endpoint)

  • 27% relative reduction in the severity (incidence of Grade 4 OM) of SOM in the avasopasem treatment group (24%) vs. placebo group (33%) (p=0.167) (secondary endpoint)

  • Avasopasem was generally well tolerated with similar rates of adverse events in the active and placebo arms

Dr. Sorensen continued, “We continue to be excited about the potential of our second dismutase mimetic product candidate, GC4711, in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC). We recently initiated a Phase 2b trial of GC4711 in combination with SBRT in LAPC based on promising tumor and survival outcome benefits observed in a Phase 1/2 pilot trial. In addition, enrollment is ongoing in a Phase 1/2 trial of GC4711 in combination with SBRT in patients with NSCLC. We look forward to providing updates as these trials progress.”

The ROMAN trial is a randomized, double-blind, placebo-controlled trial in 455 patients with locally advanced HNC receiving seven weeks of standard-of-care radiotherapy plus cisplatin. Patients were randomized to one of the two treatment groups (3:2) to receive 90 mg of avasopasem or placebo by infusion on the days they receive their radiation treatment.

Monday, October 18, 2021

PROG: Short float | Yahoo -> Finance -> Conversation - Ortex info

 9 hours ago

PROG- Fintel data now: Short Shares Availability -1000 / Short Squeeze Score - 1 out of 5470 / Short Borrow Rate - 74.56% / FINRA Dark Pool
Short Volume Ratio- 54.01 / Officer Accumulation : 95.80 - placed 20 out of 11503 / Insider Accumulation : 69.39 - placed 2159 out of 13627
jasime
How are you feeling about PROG?
  • ghita
    9 hours ago
    @Phil Brother, why the hell should anyone sell with all this amazing data? That’s the safest investment and the most probable short squeeze from the recent history of trading!! No offering possible till 20th Nov! Huge market! Huge potential and possible great deal with Pfizer! A 50% buyout chance it’s the most pessimistic scenario for this stock and that will at least triple the investment… People staying !
  • Phil
    9 hours ago
    So do you think it will be a sell off again
  • 2 days ago
    6 different catalysts for PROG: Athyrium (holds 47% and CVI 10%) buyout at $8-$10. Selling division for $80 million, 2 new big undisclosed partnerships announced, new FDA approvals, Highest squeeze potential and more.
  • 9 hours ago
    These impossible levels people are pointing out like 10-15 are actually not even out of the equation. BBIG is an example, started at 2-3 and within 2 weeks saw 12 before selling off. So let’s see, sky is the limit
  • $PROG conversation
    Here's the current Ortex info. Shorts haven't even begun to cover!
    Estimated
    Short Interest Change
    +1.36%
    Estimated
    Current SI % of FF
    63.93%
    Estimated
    Current SI
    30.67m
    Returned Shares
    415.9k
    Borrowed Shares
    861.97k
    Borrowed Change
    446.07k
    CTB Min
    74.9%
    CTB Avg
    141.99%
    CTB Max
    259.51%
    Utilization
    Current
    99.88
    7 days ago
    99.64
    % Change
    0.24
  • Duke
    3 days ago
    $BBIG conversation
    Morning short report! Lets push those options in the money troops!
    Today's Changes - Live Updates
    Changes from Friday 7am (ET)
    Estimated
    Short Interest Change
    +0.73%
    Estimated
    Current SI % of FF
    25.49%
    Estimated
    Current SI
    23.88m
    Returned Shares
    103.15k
    Borrowed Shares
    353.21k
    Borrowed Change
    250.06k
    CTB Min
    39.18%
    CTB Avg
    220.95%
    CTB Max
    259.51%
    Utilization
    Current
    99.98
    7 days ago
    99.14
    % Change
    0.85

Prog stock: Short squeeze | Understand short squeeze | float short

 Oct. 18, 2021

My notes: 

  1. Google Fintel's Short Squeeze leaderboard - Prog, score of 97.43

Why Progenity Stock Is Soaring on Tuesday

The biotech stock, which has had a volatile year, is a favorite of retail investors because of its potential for a short squeeze.

Jim Halley
(TMFjimhalley)
Oct 12, 2021 at 3:50PM

Key Points

  • Progenity lost $78.5 million in the second quarter.
  • The company's stock has been heavily shorted.
  • It received a patent last month for a prenatal test.

What happened

Progenity (NASDAQ:PROG

×​

) saw its shares rise more than 11% on Tuesday. The company's stock opened at $2.10 a share, then rose to as high as $2.70 a share in midday trading. The stock has been volatile. It is down more than 74% for the year but is up more than 128% the past three months. It is well off its 52-week high of $9.48 a share.

) saw its shares rise more than 11% on Tuesday. The company's stock opened at $2.10 a share, then rose to as high as $2.70 a share in midday trading. The stock has been volatile. It is down more than 74% for the year but is up more than 128% the past three months. It is well off its 52-week high of $9.48 a share.

So what

The biotech company specializes in molecular testing products. Its last real news was last month when it announced it was able to patent Preecludia, its test to rule out preeclampsia, which is when pregnant women or new mothers develop high blood pressure and high protein levels that can cause complications with the liver, kidneys, the lungs or even seizures. The company's assay measures for free and dissociated placental growth factor, a biomarker for preeclampsia. At this point, Preecludia is still in clinical testing.

With no big news coming out for more than a month, the reason for the stock's rise is likely that retail investors see its potential for a short squeeze. It tops the list for Fintel's Short Squeeze leaderboard with a score of 97.43.

Now what

The stock is a gamble because it is a young company with little revenue and only a few products, mostly prenatal screening tests. In the second quarter, it reported revenue of $463,000, up $1,772% year over year, but it had a net loss of $78.5 million compared to a loss of $32.3 million in the same period in 2020. It said it plans to cut costs to focus on its pipeline.

It does have a decent-sized pipeline in women's health, gastrointestinal health, and oral biotherapeutics. For the time being, it is pinning a lot of hope on getting Preecludia approved. If that happens, it would be the first single test to rule out preeclampsia, which is one of the leading causes of maternal morbidity.

Like many early-stage biotech companies, there are a lot of ifs in Progenity's future. It's safe to say that investing in the stock is risky, in the short term or long term.



Stock concepts: Short float | raw short | 10 minutes to study

 

Short Float: What It Is, How to Identify It, & Examples

Breakfast and learn: Chevron CEO Wirth on rising oil prices and transition to green energy | Crude oil price up | investing on oil stock

Oct. 18, 2021

Here is the link. 

Chevron CEO Mike Wirth sits down with CNBC's David Faber to discuss growing oil prices and how the U.S. should effectively transition to clean energy. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-n...

OXY stock: Crude oil price $83 | My plan to invest

 Oct. 18, 2021

My notes:

  1. OXY - target price $50 | Truist analyst 
  2. quarterly dividend 
  3. stock repurchase program
  4. 20-month high on Oct. 8
  5. Soared 82.9% YTD
  6. 5 day lost 5.9% over past 5 days



Occidental Petroleum stock rallies after Truist analyst upgrades, boosts price target to Street high

Published: Oct. 18, 2021 at 7:50 a.m. ET

Shares of Occidental Petroleum Corp. OXY, +4.82% rallied 2.3% in premarket trading Monday, putting them on track to snap a five-day losing streak, after Truist analyst Neal Dingmann became Wall Street's most bullish on the oil and natural gas exploration and production company, citing expectations that record free cash flow will continue. Dingmann raised his rating to buy from hold. He raised his price target to $50, which implies a 58% gain off Friday's closing price of $31.66, from $35. That is now the highest price target among the 29 analysts surveyed by FactSet. "[W]e believe the company will soon discuss plans to return its quarterly dividend to 2019/2020 levels along with the further possibility of an additional variable dividend and/or stock repurchase program," Dingmann wrote in a note to clients. "Further, [Occicental's] decarbonizing operations continue to gain steam capitalizing on its notable infrastructure in place/under development." Occidental's stock, which had lost 5.9% over the past five days, since it closed at a 20-month high on Oct. 8, has soared 82.9% year to date through Friday, while crude oil futures CL00, +0.26% have run up 71.9%, natural gas futures NG00, -4.14% have rocketed 110.4%, the SPDR Energy Select Sector ETF XLE, +0.49% has rallied 51.3% and the S&P 500 SPX, +0.16% has advanced 19.0%.

Sunday, October 17, 2021

Google research : Francisco blanch oil

Oct. 17, 2021

Here is the link. 

Oct.13 -- The energy crisis could cause oil prices to hit $100 a barrel sooner than expected says Bank of America's Francisco Blanch. He spoke to David Westin on "Bloomberg Balance of Power."

Oil Could Hit $100 Sooner Than Expected, Blanch Says

Oct. 17, 2021

Here is the link. 

Oct.13 -- The energy crisis could cause oil prices to hit $100 a barrel sooner than expected says Bank of America's Francisco Blanch. He spoke to David Westin on "Bloomberg Balance of Power."